Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with a focus on neuroscience and intranasal pherine product candidates. The VTGN news feed highlights the company’s progress as it advances its nose-to-brain neurocircuitry platform for conditions such as social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause.
News about Vistagen frequently covers clinical trial milestones, including updates from its PALISADE Phase 3 public speaking challenge studies of fasedienol for the acute treatment of social anxiety disorder. These items may include announcements that randomized, double-blind, placebo-controlled trial phases have been completed, topline results from specific studies such as PALISADE-3, and commentary on how outcomes compare with earlier trials like PALISADE-2. The company also reports on exploratory and nonclinical data for other pherine candidates, such as PH80 for menopausal hot flashes, including findings on brain and autonomic effects and mechanistic insights presented at scientific meetings.
Investors and observers can also find corporate and governance updates in Vistagen’s news, such as board appointments, executive leadership changes, and participation in healthcare and neuropsychiatry conferences. Press releases may discuss new director appointments, additions to the executive team, and information about investor presentations and conference webcasts.
For those tracking VTGN, the news stream offers a consolidated view of clinical, scientific, and corporate developments that shape the company’s pherine pipeline and regulatory strategy. Regularly reviewing these updates can provide context on trial outcomes, regulatory designations, and Vistagen’s stated plans for its late-stage programs in mental health and women’s health.
Vistagen (VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and developing intranasal pherine products, has announced its participation in the upcoming Jefferies 2025 Global Life Sciences Conference in New York. The company's CEO, Shawn Singh, will engage in a fireside chat on June 5, 2025, at 11:40 a.m. ET. Investors can access the presentation through a live webcast on Vistagen's website's Investors section, with a replay available afterward.
[]Vistagen (VTGN), a clinical-stage biopharmaceutical company focused on neuroscience, will present two posters at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The first presentation on May 28 will discuss the age of onset of Social Anxiety Disorder (SAD) from fasedienol clinical trials. The second presentation on May 29 will explore how itruvone, their investigational pherine for major depressive disorder, affects nasal chemosensory receptors and olfactory bulb physiologic activation through specific biomarkers. Both posters will be available on Vistagen's website on June 2, 2025.
Vistagen (VTGN) presented new research on Social Anxiety Disorder (SAD) at the 2025 ADAA Conference, building on findings from the 2024 NEI Congress. The research reveals that SAD affects nearly 31 million U.S. adults, with increasing prevalence especially among young adults aged 18-22.
Key findings show that while SAD prevalence has increased, diagnosis rates remain stagnant and treatment rates have decreased. Over 20% of adults with SAD reported suicidal ideation, and 75% experienced mild to severe depression. In the 18-22 age group, 48.1% reported suicidal ideation, showing higher depression rates and worse mental health outcomes than those without SAD.
Data from Vistagen's fasedienol PALISADE Phase 3 studies revealed that 30% of participants had SAD onset at age 10 or younger, with an average 27-year delay before first treatment. The research emphasizes the urgent need for improved diagnosis, treatment options, and social support mechanisms.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and nose-to-brain neurocircuitry, will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas from April 3-5, 2025.
The company will showcase two poster presentations focusing on social anxiety disorder (SAD):
- On April 4, 2025: Research on age of onset of SAD in fasedienol (PH94B) nasal spray trials (Poster F40)
- On April 5, 2025: A cross-sectional study examining SAD among young adults aged 18-22 using US National Health and Wellness Survey data (Poster S109)
Both posters will be made available on Vistagen's website on April 7, 2025. The presentations highlight the company's work with pherines, a new class of intranasal product candidates.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and nose-to-brain neurocircuitry, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum. The company's President and CEO, Shawn Singh, will engage in a fireside chat presentation on March 18, 2025, at 12 p.m. Eastern Time.
The company specializes in developing and commercializing a novel class of intranasal product candidates called pherines. Interested parties can access the live webcast through the 'Events' page in the 'Investors' section of Vistagen's website, with a replay available after the event.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's President and CEO, Shawn Singh, will deliver a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time.
The presentation will be accessible via webcast through the 'Events' page in the 'Investors' section of Vistagen's website. Investors and interested parties can access the replay of the webcast, which will be archived on the company's website after the event.
Vistagen (VTGN) reported its fiscal Q3 2025 financial results and provided updates on its clinical pipeline. The company's PALISADE Phase 3 Program for fasedienol in social anxiety disorder is advancing with PALISADE-3, PALISADE-4, and Repeat Dose trials, with top-line results expected later in 2025.
The company reported positive results from a Phase 2A trial of PH284 in cancer cachexia, marking their fifth pherine product candidate with positive efficacy signals. Financial results show R&D expenses increased to $11.3 million from $4.5 million year-over-year, while G&A expenses rose slightly to $4.0 million from $3.8 million. Net loss widened to $14.1 million compared to $6.4 million in the same period last year. The company maintained a strong cash position of $88.6 million as of December 31, 2024.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and pherine-based intranasal treatments, has scheduled its fiscal year 2025 third quarter financial results conference call and webcast for February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The company will present results for the quarter ended December 31, 2024, along with a corporate update.
The event will be accessible via webcast through the company's website under the 'Events' section of the Investors area. Participants can register online to receive dial-in information and a unique PIN for the live call, with recommended joining 15 minutes before the start time. A replay will be available on Vistagen's website within 24 hours and remain accessible for at least 90 days.